Dozens of biotech companies are ‘free’ for investors’ taking By: MarketWatch February 16, 2016 at 05:12 AM EST They’re trading at less than net cash, making them bargains — and also risky, so buyer beware, says Michael Brush. Read More >> Related Stocks: Achison Inc Amgen Arbutus Biopharma Corp Biogen Idec Bluebird Bio Celgene Corp Flex Pharma Inc Gilead Sciences Johnson & Johnson Merck & Co Prothena Corp Range Cancer Therapeutics Index Retrophin Inc Roche Holding AG Basel American Depositary Shares Sangamo Therapeutics Shire Plc Ads Trillium Therapeutic